Abstract: Novel topical compositions for the treatment of nail and skin afflictions comprising at least one active agent, at least one volatile solvent, at least one film-forming ingredient and at least one phospholipid, processes for their preparation and methods of treatment of nail and skin afflictions. Following application of the compositions and evaporation of volatile solvents, the composition produces a film, which has web-like structures containing the active agent(s).
Type:
Grant
Filed:
August 1, 2011
Date of Patent:
June 6, 2017
Assignee:
YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD.
Abstract: A solid oral pharmaceutical composition in the form of tablets including:—a first solid oral pharmaceutical formulation in the form of at least one micro-tablet, the micro-tablet consisting of a core including at least one Krebs cycle precursor salt as active ingredient, and of a coating including at least one coating agent, and—a second oral pharmaceutical formulation in the form of at least one mini-tablet, the mini-tablet consisting of a core including at least one bicarbonate salt as active ingredient and at least one prolonged-release matrix, and of a coating including at least one coating agent. The use thereof as a medicament, in particular in the treatment and/or prevention of cystinuria.
Abstract: Disclosed is a method for the preparation of easily-swallowed, reliably-dosed, aesthetically-improved tablets of sodium ibuprofen dihydrate, the method comprising the formation of the tablets with punches or presses comprising contact surfaces which are chrome or chrome-plated.
Type:
Grant
Filed:
December 14, 2012
Date of Patent:
April 25, 2017
Assignee:
SI GROUP, INC.
Inventors:
Latria N. Boudoin, Gregory H. Lambeth, Eric W. Llimatta, Patrick C. Hu
Abstract: Granules of racemic sodium ibuprofen dihydrate formed from components specified herein have very desirable properties and can be effectively used in conventional rotary press tableting equipment without operational difficulties often encountered in actual practice. Their preparation by a wet granulation process, the wet granule compositions, formulations adapted for preparation of solid dosage forms utilizing a rotary press, solid dosage forms, and methods of preparing solid dosage forms in a rotary press are also described.
Abstract: Compositions may include a pharmaceutical active agent, a high viscosity liquid carrier material (HVLCM), a lactic acid-based polymer, and an organic solvent. Related compositions and methods are also disclosed.
Type:
Grant
Filed:
January 14, 2016
Date of Patent:
February 21, 2017
Assignee:
DURECT CORPORATION
Inventors:
Jeremy C. Wright, Wilma Tamraz, John J. Leonard, John W. Gibson, Keith E. Branham, Stefania Sjobeck, Brooks Boyd, Christopher M. Rubino
Abstract: The invention relates to medicine, and specifically to synthetic biologically active derivatives of carbopentoxysulfanilic acid. The novel substance comprises a (2,6-dichlorophenyl)amide salt of carbonpentoxysulfanilic acid of general formula: wherein X is Na, K, NH4; the drug may be contained in tablets, including sublingual tablets, or in capsules, or in suppositories, or in drops, or in mixtures, or in ointments, creams or other forms for application to the skin and mucosae, or in an oral-buccal film, or in a spray, or in a liquid for parenteral administration, or in chewing gum. A preparation having pronounced activity against herpes viruses is thus produced.
Type:
Grant
Filed:
January 28, 2011
Date of Patent:
February 14, 2017
Inventors:
Viktor Veniaminovich Tets, Georgy Viktorovich Tets, Viktor Iosifovich Krutikov
Abstract: An energy tablet and method of manufacturing the same that successfully masks the bitter taste of caffeine which has precluded popularity of chewable energy tablets in the past.
Abstract: The invention relates to an orally administrable chewable composition in unit dosage form comprising an oil-in-water emulsion in which the aqueous phase is gelled and in which the oil phase comprises a physiologically tolerable unsaturated fatty acid ester.
Abstract: Disclosed are biodegradable microspheres between 40 ?m and 200 ?m in diameter that are effectively retained in the anterior chamber of the eye without producing hyperemia. The microspheres generally contain a drug effective for the treatment of an ocular condition and include a biodegradable polymer matrix that can provide for the sustained (>7 day) release of the drug following administration to the anterior chamber of the eye. Methods for making and using the microspheres to treat an ocular condition are also disclosed.
Type:
Grant
Filed:
March 14, 2014
Date of Patent:
November 29, 2016
Assignee:
Allergan, Inc.
Inventors:
Hui Liu, Jinping Wan, Patrick M. Hughes
Abstract: The present invention relates to a method for extracting phenolic compounds with low molecular weights from olive fruit water; the invention also relates to compositions enriched with phenolic compounds including at least 40% of dry matter, said dry matter consisting of at least 30% hydroxytyrosol; the invention also relates to a method for drying said compositions by spraying using grape polyphenol extracts as a drying medium as well as to powders titrated with phenolic compounds of olives and grapes obtained after drying.
Type:
Grant
Filed:
February 18, 2010
Date of Patent:
November 1, 2016
Assignees:
Centre de Cooperation Internationale en Recherche Agronomique Pour le Developpement (CIRAD), GRAP'SUD, Centre International d'Etudes Superieures en Sciences Agronomiques (Montpellier Sup Agro)
Inventors:
Nelly Urban, Manuel Dornier, Dominique Pallet, Max Reynes
Abstract: A smart antimicrobial material and dressing to inhibit microbial growth is provided. Endogenous chemicals, such as metabolites produced from bacteria are utilized as chemical substrates and converted by enzymes to produce a disinfecting compound that will in turn inhibit the targeted microorganism. The material shall remain passive until such time as it encounters a microbe which expresses and/or secretes specific metabolites or markers. The enzyme or enzymes embedded in the smart material converts the metabolite into a disinfecting compound, which in turn either kills the microorganism or prevents it from multiplying on the surface of the material.
Type:
Grant
Filed:
June 12, 2013
Date of Patent:
September 27, 2016
Assignee:
FLIR Detection, Inc.
Inventors:
Anna M. Leech, Jeremy P. Walker, Scott Donahue, Jermaine D. Johnson, Jessica J. Sinclair
Abstract: The present invention relates to a personal care composition with a synthetic random copolymer having a net positive charge, a detersive surfactant; and an aqueous carrier.
Type:
Grant
Filed:
January 8, 2007
Date of Patent:
August 30, 2016
Assignee:
The Procter & Gamble Company
Inventors:
Marjorie Mossman Peffly, Mark Anthony Brown, James Anthony Staudigel, Jun Ji Zhang
Abstract: A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum.
Abstract: The present invention relates to stable pharmaceutical formulations that include a delivery agent and/or pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
June 28, 2007
Date of Patent:
June 14, 2016
Assignee:
EMISPHERE TECHNOLOGIES, INC.
Inventors:
Shingai Majuru, Moses O. Oyewumi, Mehmet Tahir Gurler
Abstract: A biogel, and kits, agents, and methods for formation of the biogel are described. The biogel can be used for a variety of applications, including haemostasis, wound sealing, tissue engineering or localized drug delivery.
Abstract: Disclosed are oral care compositions, for example dentifrice compositions, comprising an orally acceptable vehicle, metal oxide particles having an average particle size of no greater than a dentin tubule and a polymeric adherent material for adhering the metal oxide particles in the dentin tubule. The metal oxide particles have a median particle size of 5 microns or less, and may comprise zinc oxide.
Type:
Grant
Filed:
March 31, 2010
Date of Patent:
April 26, 2016
Assignee:
Colgate-Palmolive Company
Inventors:
Venda Porter, Andre Morgan, Michael Prencipe, Sarita Mello
Abstract: The composition for treating ocular effects of diabetes is a composition that contains an aldose reductase inhibitor in an ophthalmic gel for topical application to the eye. The composition includes a carrier having, by weight, about 0.4% carbomer, 4.0% sorbitol, 0.01% centrimide, 0.01% ethylenediaminetetraacetic acid (EDTA) and effective amounts of sodium chloride and sodium hydroxide for adjusting the pH of the topical carrier to about 7 and to achieve a desired viscosity, with the balance being water. The aldose reductase inhibitor (ARI) is mixed with the topical carrier at about 0.1%-6% by weight of the composition to form an ophthalmic gel. Preferably, the ARI is 2R,4S-6-fluoro-2-methyl-spiro[chroman-4,4?-imidazolidine]-2?,5?-dione, referred to as 2-methyl sorbinil, having the structure: or a pharmaceutically acceptable salt thereof. In use, the ophthalmic gel is preferably applied as an eye drop at a dosage of one drop per eye administered two to three times daily.
Abstract: The present invention provides surface-stabilized amorphous pharmaceuticals comprising an amorphous pharmaceutical substrate coated with a biocompatible immobilizing material. Amorphous pharmaceutical substrates that are prone to surface enhanced crystallization benefit from the present coatings. The coated amorphous pharmaceuticals of the present invention maintain their amorphous state and, therefore, their solubility over extended periods of time, relative to uncoated pharmaceuticals.
Type:
Grant
Filed:
March 21, 2008
Date of Patent:
February 9, 2016
Assignee:
Wisconsin Alumni Research Foundation
Inventors:
Lian Yu, Melgardt M. De Villiers, Tian Wu
Abstract: The present invention provides a delayed and/or controlled release formulation of paroxetine or a pharmaceutically acceptable salt thereof that is formulated to release a substantial portion of the active ingredient (e.g., paroxetine) in the large intestine of an individual in need thereof. In one embodiment, the present invention provides a controlled release paroxetine composition comprising paroxetine or a pharmaceutically acceptable salt thereof, in a controlled release swallow pharmaceutical formulation, that upon administration, releases the paroxetine substantially in the large intestine. For example, the controlled release paroxetine formulation may be formulated to release greater than about 50% of the paroxetine in the large intestine.
Type:
Grant
Filed:
December 27, 2007
Date of Patent:
September 22, 2015
Assignee:
Mylan Specialty L.P.
Inventors:
Jason Neely, David J. Wargo, Boyong Li, Thomas D. Reynolds